Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Financing Activities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Cash from Financing Activities for 4 consecutive years, with -$97000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 100.37% to -$97000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$288000.0, a 100.16% decrease, with the full-year FY2025 number at -$288000.0, down 100.16% from a year prior.
  • Cash from Financing Activities was -$97000.0 for Q4 2025 at Phathom Pharmaceuticals, up from -$271000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $212.0 million in Q4 2023 to a low of -$271000.0 in Q3 2025.
  • A 4-year average of $47.9 million and a median of $19.3 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 938800.0% in 2024, then plummeted 100.37% in 2025.
  • Phathom Pharmaceuticals' Cash from Financing Activities stood at $24.6 million in 2022, then surged by 761.9% to $212.0 million in 2023, then crashed by 87.71% to $26.0 million in 2024, then tumbled by 100.37% to -$97000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Cash from Financing Activities are -$97000.0 (Q4 2025), -$271000.0 (Q3 2025), and $80000.0 (Q2 2025).